Method for prevention of neutropenia in patients suffering chronic hepatitis c and receiving antiviral combination therapy

FIELD: medicine. SUBSTANCE: invention may be applicable to prevent neutropenia developing in the patients suffering chronic hepatitis C (CHC) in response to conducting an antiviral combination therapy (ACT). The method for preventing neutropenia in the CHC patients receiving the ACT is characterised by introducing autoblood haemolysate (ABH) 20.0 ml intravenously daily to the CHC patients in need of the ACT and having a high risk of ACT-associated neutropenia, 10 days exactly before the ACT beginning; from the very beginning and throughout the entire course of the ACT, the ABH intravenous administration continues in the same dose, however performed every 7 days. During the ABH intravenous administration, patient's blood 10.0 ml is taken from median cubital vein into a syringe 20.0 ml 50% pre-filled with distilled water; thereafter, leaving a puncture needle in the vein, the ABH produced in the syringe is introduced back into the vascular bed. EFFECT: method enables the effective prevention of neutropenia accompanying the ACT in the CHC patients with the use of the autoblood haemolysate. 1 tbl, 1 ex